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1.31), p=0.91; 74Gy vs 57Gy: HR 1.02 (0.74-1.30), p=0.86). 
Analysis of change from pre-RT showed no evidence of a 
difference between treatment groups (figure 1).  
 
 
 
The odds of an increase in overall bowel bother were reduced 
(compared to the 74Gy control arm) by 11% (odds ratio (OR) 
0.89 99% CI: (0.62-1.27), p=0.4) and 8% (OR 0.92 (0.77-1.10), 
p=0.24) in the 60Gy and 57Gy groups respectively. For overall 
urinary bother, odds of an increase were increased by 31% 
(OR 1.31, (0.93-1.85) p=0.04) and 2% (OR 1.02 (0.86-1.20), 
p=0.79) for the 60Gy and 57Gy groups respectively. 
Conclusions: Overall bowel bother and overall urinary bother 
was low in the CHHiP trial, cross sectional and longitudinal 
analysis found no evidence of differences between either 
hypofractionated arm and the 74Gy control arm to 24 months 
of follow up.  
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Purpose/Objective: To evaluate the feasibility and 
preliminary toxicity results of a prospective randomized 
multicenter phase II trial of short vs. protracted urethra-
sparing stereotactic body radiotherapy (SBRT) for localized 
prostate cancer. 
Materials and Methods: A total of 93 cT1-3a N0 M0 prostate 
cancer patients with a lymph-node involvement risk ≤ 20% 
were randomized between September 2012 and October 2014 
to be treated with an SBRT protocol of 36.25 Gy in 5 fractions 
of 7.25 Gy either over 9 days (Arm A, n=45) or over 28 days 
once-a-week, the same week-day (Arm B, n=48). The dose to 
the prostatic urethra with a surrounding margin of 3 mm 
(urethral planning risk volume, uPRV) was reduced to 32.5 Gy 
in 5 fractions (NTD2Gy of 74 and 62 Gy for an α/β ratio of 1.5 
and 3 Gy, respectively). Tolerance to the treatment was 
scored using the Common Toxicity Criteria for Adverse Events 
ver. 4.0 grading scale, the International Prostate Symptom 
Score (IPSS) and the EORTC QLQ-PR25 quality of life (QoL) 
questionnaire. Thirty-seven patients in Arm A and 38 patients 
in Arm B have completed treatment. Their follow-up (FU) 
extended up to 18 months and in Arm A 70% has reached their 
six month evaluation, while 60% of the patients in Arm B did. 
Results: SBRT was delivered to all patients as planned with 
no treatment interruptions. Overall genitourinary and 
gastrointestinal toxicities were below the stopping rule 
established for the study, with grade 2 toxicity reported in 6 
patients for each arm mostly after the 5th fraction. Only one 
patient experienced late grade 3 rectal toxicity, with the 
need of blood transfusion and endoscopic coagulation for the 
bleeding, between the 7th and 12th month FU. Mean IPSS 
scores increased significantly between baseline and the 5th 
fraction (p<0.01) in both treatment arms, returning to 
baseline at week 12. Mean IPSS values at baseline, after the 
5th fraction and after 12 weeks were 7.5, 14 and 7.5 for Arm 
A and 8.1, 12.7 and 8.9 for Arm B, respectively. No 
significant differences were observed in EORTC QLQ-PR25 
QoL endpoints between baseline and week 12 in either study 
arm.  
Conclusions: Preliminary results demonstrated the feasibility 
and the acceptable toxicity rates of this short vs. protracted 
urethra-sparing prostate SBRT phase II trial. Three months 
after randomization complete recovery from side effects and 
return to baseline IPSS scores was observed in both treatment 
schedules.  
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Purpose/Objective: The combination of adjuvant hormone 
therapy (HT) with radiotherapy (RT) improves prognosis in 
patients with intermediate-high risk prostate cancer (PCa). 
